Core Viewpoint - The acquisition of control over Awei Co., Ltd. (002559.SZ) by the state-owned assets of Yangzhou is progressing, with a revised private placement plan that reduces the number of shares and fundraising amount, moving closer to completion of the transaction [1][3]. Group 1: Acquisition Details - Awei Co., Ltd. has adjusted its private placement plan, reducing the number of shares from 99.72 million to 92.09 million and the fundraising amount from 719 million to 664 million yuan [1][5]. - Upon completion, Yangzhou Industrial Investment Development Group will hold 14.35% of Awei's shares, becoming the actual controller of the company [1][3]. - The control transfer marks the re-entry of Yangzhou state-owned assets into the A-share market after nearly 20 years, with Awei becoming the second listed company controlled by Yangzhou state assets after Lianhuan Pharmaceutical [1][13]. Group 2: Historical Context - Awei Co., Ltd. was listed in March 2011, originally controlled by founders Leng Zhibin and Ji Suqin, who held 26.1% of the shares at the time of listing [3][5]. - The company has faced challenges in capital operations, previously attempting to introduce strategic investors and transfer control, all of which failed [5][12]. - The initial plan for the private placement aimed to raise approximately 934 million yuan, which has since been significantly reduced [5][12]. Group 3: Financial Performance - Awei's revenue has increased due to multiple acquisitions, but its profitability has stagnated, with annual profits fluctuating around 100 million yuan [12]. - The company's gross profit margin has declined from nearly 30% in 2019 to approximately 22% in the first three quarters of 2025, indicating a mismatch between revenue growth and profitability [12]. - The debt level has risen significantly, with the asset-liability ratio increasing from about 30% in 2018 to around 63% by the end of the third quarter of 2025 [12]. Group 4: Strategic Importance - Yangzhou Industrial Investment Development Group, as a state-owned platform, is expected to conduct thorough evaluations before making investments, indicating a strategic approach to the acquisition [8][9]. - Awei Co., Ltd. is recognized as a key player in the metal forming machine tool industry, with its products widely used across various sectors, including automotive and aerospace [9][12]. - If the acquisition is successful, it will break the long-standing situation where Lianhuan Pharmaceutical was the only listed company controlled by Yangzhou state assets [13][15].